Business Context and Reporting Period
CalciMedica, Inc. (CALC) filed a Current Report on Form 8-K on May 8, 2023. The Company is an emerging growth company incorporated in Delaware. Its common stock began trading on the OTC QB on April 26, 2023. This filing addresses a material restatement of financial statements for the year ended December 31, 2022.
Key Financial Metrics
This filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the qualitative impact of accounting errors regarding the valuation of convertible promissory notes and warrant liabilities as of December 31, 2022.
Material Changes and Restatement Details
The Board of Directors, following the Audit Committee's recommendation and discussion with Ernst & Young LLP, concluded that previously issued financial statements for the year ended December 31, 2022, should no longer be relied upon. The errors stemmed from valuation models that failed to appropriately consider the estimated conversion computation included in the Agreement and Plan of Merger and Reorganization with Graybug Vision, Inc.
- Accounting Error: Incorrect valuation of convertible promissory notes and warrant liability on the balance sheet.
- Expected Impact: The restatement is expected to decrease the carrying value of these liabilities, resulting in recognized gains.
- Financial Outcome: The errors are expected to decrease the reported net loss, comprehensive loss, and net loss per share attributable to common stockholders for fiscal 2022.
Outlook, Risks, and Management Commentary
Management plans to file an amendment to the original Form 8-K/A to report the restated financial statements. The specific restatement amounts remain subject to the completion of the audit by Ernst & Young LLP.
Risks and Contingencies:
- Forward-looking statements regarding the adjustments are subject to uncertainties and may not materialize.
- There are risks related to the Company's ability to maintain an effective system of internal control over financial reporting.
- Investors are directed to the "Risk Factors" section of the Form 10-Q for the quarter ended March 31, 2023, for additional details.
Investor Verification Checklist
- Verify the specific dollar amounts of the restatement once the amended Form 8-K/A is filed.
- Confirm the revised net loss and net loss per share for fiscal 2022.
- Monitor the status of the audit completion by Ernst & Young LLP.
- Review the Company's internal controls over financial reporting in subsequent filings.